Ardelyx, Inc.

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-20 pm EDT 5-day change 1st Jan Change
7.93 USD +1.47% Intraday chart for Ardelyx, Inc. -1.12% +27.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing MT
Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing MT
Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing MT
Ardelyx Shares Rise After Q1 Beat MT
Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating MT
Top Premarket Gainers MT
Transcript : Ardelyx, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M MT
Ardelyx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating MT
Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target MT
Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy CI
Ardelyx Insider Sold Shares Worth $664,978, According to a Recent SEC Filing MT
Ardelyx, Inc. announced that it has received $50 million in funding CI
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Sector Update: Health Care MT
Ardelyx's Q4 Swings to Loss; Revenues Down; Shares Down After-Hours MT
Ardelyx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Ardelyx, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (ARDX) ARDELYX Posts Q4 Revenue $34.4M, vs. Street Est of $34.2M MT
Sector Update: Health Care Stocks Slide Late Friday Afternoon MT
Sector Update: Health Care MT
Ardelyx's Xphozah to Attract 'Substantial Attention' in 2024, Wedbush Says MT
Wedbush Adjusts Price Target on Ardelyx to $13 From $9, Maintains Outperform Rating MT
Chart Ardelyx, Inc.
More charts
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.93 USD
Average target price
13.83 USD
Spread / Average Target
+74.39%
Consensus
  1. Stock Market
  2. Equities
  3. ARDX Stock
  4. News Ardelyx, Inc.
  5. Sector Update: Health Care Stocks Mixed Premarket Friday
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW